Metraipolis › archive › dc_4ed3269102bb

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants — Europe PMC PPR:PPR306316

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR306316
DOI
10.1101/2021.04.01.437942
License (as archived)
CC0-1.0
Archived
2026-11-05T03:43:33.073Z
SHA-256 of the archived text
7afb387ae8107dcd0e7b3312cb4d1a9fa72f05631381c8b8c514a138ab0a2265
Stable URL of this page
https://metraipolis.com/documento/dc_4ed3269102bb

How to cite

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants — Europe PMC PPR:PPR306316 — Europe PMC, https://europepmc.org/article/PPR/PPR306316 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_4ed3269102bb (Metraipolis archive dc_4ed3269102bb, sha256 7afb387ae8107dcd0e7b3312cb4d1a9fa72f05631381c8b8c514a138ab0a2265)
BibTeX
@misc{dc4ed3269102bb,
  title = {Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants — Europe PMC PPR:PPR306316},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR306316},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_4ed3269102bb; sha256 7afb387ae8107dcd0e7b3312cb4d1a9fa72f05631381c8b8c514a138ab0a2265},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR306316. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells of COVID-19 patients. The three most potent antibodies targeted distinct regions of the RBD, and all three neutralized the SARS-CoV-2 variants B.1.1.7 and B.1.351. The crystal structure of the most potent antibody, CV503, revealed that it binds to the ridge region of SARS-CoV-2 RBD, competes with the ACE2 receptor, and has limited contact with key variant residues K417, E484 and N501. We designed bispecific antibodies by combining non-overlapping specificities and identified five ultrapotent bispecific antibodies that inhibit authentic SARS-CoV-2 infection at concentrations of 100-fold more potent than a cocktail of its parent monoclonals in vitro and prevented clinical disease in a hamster model at a 2.5 mg/kg dose. Notably, six of nine bispecific antibodies neutralized B.1.1.7, B.1.351 and the wild-type virus with comparable potency, despite partial or complete loss of activity of at least one parent monoclonal antibody against B.1.351. Furthermore, a bispecific antibody that neutralized B.1.351 protected against SARS-CoV-2 expressing the crucial E484K mutation in the hamster model. Thus, bispecific antibodies represent a promising next-generation countermeasure against SARS-CoV-2 variants of concern.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: bioRxiv, 2021 (prima pubblicazione 2021-04-01).
Identificativi: DOI 10.1101/2021.04.01.437942.
Pagina: https://europepmc.org/article/PPR/PPR306316 — https://doi.org/10.1101/2021.04.01.437942. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-05T03:40:17.428Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.